Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Pharmacogenomics Journal is Scopus-indexed (Q2, CiteScore 5.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Nature.
Checked against the index lists dated .
ISSN 1470-269XVerify ISSN ↗1473-1150Verify ISSN ↗
Publisher: Springer Nature
Cost to publish: About US$4,890 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 114 / 328 | 65th | Q2 |
| Genetics | 126 / 357 | 64th | Q2 |
| Molecular Medicine | 89 / 179 | 50th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q2, CiteScore 5.7.
Pharmacogenomics Journal is Q2 in Pharmacology (rank 114 of 328), Q2 in Genetics (rank 126 of 357) and Q2 in Molecular Medicine (rank 89 of 179), by CiteScore 2025.
Pharmacogenomics Journal is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.7, which places it in quartile Q2 at the 65th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.760, quartile Q2, with an H-index of 101.
The publisher lists an article processing charge of about US$4,890 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Pharmacogenomics Journal is published by Springer Nature. Its print ISSN is 1470-269X and its online ISSN is 1473-1150.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Pharmacogenomics Journal has an h-index of 110 and a 2-year mean of 3.79 citations per paper (OpenAlex). Its Scopus CiteScore is 5.7, quartile Q2. On 2-year citations it ranks #82 of 319 Scopus journals in Pharmacology.
Pharmacogenomics Journal published 34 papers in 2025; its busiest recent year was 2019 with 75. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2024–2026), authors are most often from United States (29.5%), United Kingdom (9.5%) and China (9.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (1.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.